Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: Implications for the development of a SOCS-1 antagonist

Journal of Immunology

Volumn 178, Issue 8, 2007, Pages 5058-5068

  Waiboci, Lilian W ^a   Ahmed, Chulbul M ^a   Mujtaba, Mustafa G ^a,b   Flowers, Lawrence O ^a,c   Martin, James P ^a   Haider, Mohammed I ^a   Johnson, Howard M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b FLORIDA GULF COAST UNIVERSITY   (United States)

^c FAYETTEVILLE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; JANUS KINASE 2; PROTEIN TKIP; PROTEIN TYROSINE KINASE INHIBITOR; STAT1 ALPHA PROTEIN; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 1 ANTAGONIST; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 34247172195     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.8.5058     Document Type: Article

References (32)

1. Yamoaka, K., P. Saharinen, M. Pesu, V. E. Holt III, O. Silvennoinen, and J. J. O'Shea. 2004. The Janus kinases. Genome Biol. 5: 253-258.
2. Parganas, E., D. Wang, D. J. Stravapodis, D. Topham, J. C. Marine, S. Teglund, E. F. Vanin, S. Bodner, O. Colamonici, J. M. Deursen, et al. 1998. JAK2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395.
3. Subramaniam, P. S., B. A. Torres, and H. M. Johnson. 2001. So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors. Cytokine 15: 175-187.
4. Johnson, H. M., P. S. Subramaniam, S. Olsnes, and D. A. Jans. 2004. Trafficking and signaling pathways of molecular localizing protein ligands and their receptors. BioEssays 26: 993-1004.
5. Kotenko, S. V., and S. Pestka. 2000. JAK-STAT signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19: 2557-2567.
6. Bromberg, J., and J. E. Darnell, Jr. 2000. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473.
7. Starr, R., T. A. Willson, E. M. Viney, L. J. L. Murray, J. R. Rayner, B. J. Jenkins, T. J. Gonda, W. S. Alexander, D. Metcalf, N. A. Nicola, and D. J. Hilton. 1997. A family of cytokine-inducible inhibitors of signaling. Nature 387: 917-921.
8. Endo, T. A., M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, K. Mitsui, A. Matsumoto, S. Tanimura, M. Ohtsubo, H. Misakawa, et al. 1997. A new protein containing SH2 domain that inhibits JAK kinases. Nature 387: 921-924.
9. Naka, T., M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Anono, N. Nashimoto, T. Kajita, T. Taga, K. Yoshizaki, et al. I997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-929.
10. Alexander, W. S. 2002. Suppressors of cytokine signaling (SOCS) in the immune system. Nat. Rev. Immunol. 2: 410-416.
11. Larsen, L., and C. Röpke. 2002. Suppressors of cytokine signaling: SOCS. APMIS 110: 833-844.
12. Alexander, W. S., and D. J. Hilton. 2004. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of immune responses. Annu. Rev. Immunol. 22: 503-529.
13. Calo, V., M. Migliavacca, V. Bazan, M. Macaluso, M. Busemi, N. Gebba, and A. Russo. 2003. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 197: 157-168.
14. Flowers, L. O., H. M. Johnson, M. G. Mujtaba, M. R. Ellis, S. M. Haider, and P. S. Subramaniam. 2004. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function. J. Immunol. 172: 7510-7518.
15. Yasukawa, H., H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, T. Imaizumi, T. Matsuda, J. N. Ihle, and A. Yoshimura. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18: 1309-1320.
16. Flowers, L. O., P. S. Subramaniam, and H. M. Johnson. 2005. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 24: 2114-2120.
17. Mujtaba, M. G., L. O. Flowers, C. B. Patel, R. A. Patel, M. I. Haider, and H. M. Johnson. 2005. Treatment of mice with the suppressor of cytokine signaling-1 peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form. J. Immunol. 175: 5077-5086.
18. Szente, B. E., I. J. Weiner, M. J. Jablonsky, N. R. Krishna, B. A. Torres, and H. M. Johnson. 1996. Structural requirements for agonist activity of a murine interferon γ peptide. J. Interferon Cytokine Res. 16: 813-817.
19. Langford, M. P., D. A. Weiget, G. J. Stanton, and S. Baron. 1981. Viral plaque-reduction assay for interferon: microplaque and regular macroplaque reduction assay. Methods Enzymol. 78: 339-349.
20. Zhang, J., G. D. Metcalf, S. Rakar, M. Asimakis, C. J. Greenhalgh, T. A. Willson, R. Starr, S. E. Nicholson, W. Carter, W. S. Alexander, et al. 2001. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc. Natl. Acad. Sci. USA 98: 13261-13265.
21. Boehn, U., T. Klamp, M. Groot, and J. C. Howar. 1997. Cellular responses to interferon γ. Annu. Rev. Immunol. 15: 749-795.
22. Thiam, K., E. Long, C. Verwaerde, C. Auriault, and H. Gras-Masse. 1999. IFNγ-derived lipopeptide: influence of lipid modification on the conformation and the ability to induce MHC class II expression on marine and human cells. J. Med. Chem. 42: 3732-3736.
23. Mujtaba, M. G., C. B. Patel, R. A. Patel, L. O. Flowers, M. A. Burkhat, L. W. Waiboci, J. P. Martin, M. I. Haider, C. M. Ahmed, and H. M. Johnson. 2006. The interferon γ mimetic peptide IFN-γ(95-133) prevents encephalomyocarditis virus infection both in tissue culture and in mice. Clin. Vaccine Immunol. 13: 944-952.
24. c-dependent cytokines in peripheral T cells. J. Biol. Chem. 278: 22755-22761.
25. Kisseleva, T., S. Bhattacharya, J. Braunstein, and C. W. Schindler. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285: 1-25.
26. Heinrich, P. C., I. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen, and F. Schaper. 2003. Principles of interleukin (IL)-6 type cytokine signaling and regulation. Biochem. J. 374: 1-20.
27. Shen, L., K. Evel-Kabler, R. Strube, and S. Y. Chen. 2004. Silencing SOCS-1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22: 1546-1553.
28. Alexander, W. S., R. Starr, J. E. Fenner, C. L. Scott, E. Handman, N. S. Sprigg, J. E. Corbin, A. L. Cornish, R. Darwiche, C. M. Owczarek, et al. 1999. SOCS-1 is a critical inhibitor of interferon γ signaling and prevents potentially fatal neonatal actions of this cytokine. Cell 98: 597-608.
29. Yoshimura, A. 2005. Negative regulation of cytokine signaling. Clin. Rev. Allergy Immunol. 28: 205-220.
30. Dickensheets, H. L., C. Venkataraman, U. Schindler, and R. P. Donnelly. 1999. Interferon activation of STAT6 by interleukin-4 in human monocytes by induction of SOCS-1 gene expression. Proc. Natl. Acad. Sci. USA 96: 10800-10805.
31. Brysha, M., J. G. Zhang, P. Bertolino, J. E. Corbin, W. S. Alexander, N. A. Nicola, D. J. Hilton, and R. Starr. 2001. Suppressor of cytokine signaling-1 attenuates the duration of interferon γ signal transduction in vitro and in vivo. J. Biol. Chem. 276: 22086-22089.
32. Weathington, N. M., and J. E. Blalock. 2003. Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network. Expert Rev. Vaccines 2: 61-73.